scispace - formally typeset
Search or ask a question

Showing papers in "Current Medicinal Chemistry in 1969"

Journal Article•
Multiple myeloma associated intestinal amyloidosis: intestinal pseudo-obstruction falsely considered as an ascites

[...]

Vladimir Milivojevic, Maja Stojanovic, Ivan Rankovic, Marjan Micev, Rada Jesic Vukicevic, Tomica Milosavljevic 
31 Dec 1969-Current Medicinal Chemistry

99 citations

Journal Article•DOI•
Editorial: Novel Therapeutic Strategies for the Treatment of Chronic Diseases

[...]

Gianluca Testa, Fabiana Passaro, Aldo Cinquegrana, Melania Palma, Pasquale Abete, Carlo G. Tocchetti 
31 Dec 1969-Current Medicinal Chemistry

56 citations

Journal Article•
Selected applications for current polymers in prosthetic dentistry - state of the art

[...]

Wang Liao, Shengnuo Fan, Yuqiu Zheng, Shaowei Liao, Ying Xiong, Yi Li, Jun Liu 
31 Dec 1969-Current Medicinal Chemistry

36 citations

Journal Article•
Old Antiprotozoal Drugs: Still viable Options for Parasitic Diseases or New Options for Other Diseases?

[...]

Sandra Cortez-Maya, Antonio Moreno-Herrera, Isidro Palos, Gildardo Rivera
31 Dec 1969-Current Medicinal Chemistry

24 citations

Journal Article•
tiRNAs & tRFs Biogenesis and Regulation of Diseases: A Review Pan Jiang

[...]

Pan Jiang and Feng Yan
31 Dec 1969-Current Medicinal Chemistry
TL;DR: The regulatory roles of tiRNAs & tRFs in translation, neurodegeneration, metabolic diseases, viral infections, and carcinogenesis are discussed in detail and the potential applications of these noncoding tRNAs as biomarkers and gene regulators in different diseases are highlighted.

23 citations

Journal Article•
The Beneficial Actions of SGLT-2 Inhibitors Beyond the Management of Hyperglycemia

[...]

Charalampos Loutradis, Eirini Papadopoulou, Elena Angeloudi, Asterios Karagiannis, Pantelis Sarafidis 
31 Dec 1969-Current Medicinal Chemistry

22 citations

Journal Article•
Tacrines for Alzheimer’s Disease Therapy. III. The PyridoTacrines

[...]

Cristóbal de los Ríos and José Marco-Contelles
31 Dec 1969-Current Medicinal Chemistry
TL;DR: The PyrTac ethyl 5-amino-2-methyl-6,7,8,9-tetrahydrobenzo[b] [1,8]naphthyridine-3-carboxylate (5f), which presents additional pharmacological properties beyond the mere cholinergic improvement, warrants attention to 5f and its further development as a new potential therapeutic agent for AD therapy.

15 citations